Search Results - "Lowrey, Bryce T"

Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens by Walters, Dustin M, Stokes, Jayme B, Adair, Sara J, Stelow, Edward B, Borgman, Cheryl A, Lowrey, Bryce T, Xin, Wenjun, Blais, Edik M, Lee, Jae K, Papin, Jason A, Parsons, J Thomas, Bauer, Todd W

“…Relevant preclinical models that recapitulate the key features of human pancreatic ductal adenocarcinoma (PDAC) are needed in order to provide biologically…”
Get full text

Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib by Walters, Dustin M, Lindberg, James M, Adair, Sara J, Newhook, Timothy E, Cowan, Catharine R, Stokes, Jayme B, Borgman, Cheryl A, Stelow, Edward B, Lowrey, Bryce T, Chopivsky, Maria E, Gilmer, Tona M, Parsons, John T, Bauer, Todd W

“…Abstract Mutations of the oncogene KRAS are important drivers of pancreatic cancer progression. Activation of epidermal growth factor receptor (EGFR) and human…”
Get full text

Acquired resistance to combination therapy with lapatinib and MEK 1/2 inhibitor GSK1120212 in an in vivo murine model of pancreatic cancer by Lindberg, James M., Walters, Dustin M, Adair, Sara J, Cowan, Catharine R, Stokes, Jayme B, Borgman, Cheryl A, Stelow, Edward B, Lowrey, Bryce T, Chopivsky, Maria E, Parsons, J Thomas, Bauer, Todd W.

“…Abstract only 208 Background: Mutations of the oncogene KRAS and activation of cell-surface receptor tyrosine kinases are important and preserved mechanisms of…”
Get full text

Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib12 by Walters, Dustin M, Lindberg, James M, Adair, Sara J, Newhook, Timothy E, Cowan, Catharine R, Stokes, Jayme B, Borgman, Cheryl A, Stelow, Edward B, Lowrey, Bryce T, Chopivsky, Maria E, Gilmer, Tona M, Parsons, John T, Bauer, Todd W

“…Mutations of the oncogene KRAS are important drivers of pancreatic cancer progression. Activation of epidermal growth factor receptor (EGFR) and human EGFR2…”
Get full text

Abstract 1592: Targeting proliferative signals in patient-derived pancreatic cancers propagated orthotopically in immunocompromised mice by Walters, Dustin M., Cowan, Catharine R., Adair, Sara J., Borgman, Cheryl A., Stokes, Jayme B., Stelow, Edward B., Lowrey, Bryce T., Gilmer, Tona M., Parsons, J. Thomas, Bauer, Todd W.

“…Abstract Pancreatic ductal adenocarcinoma (PDAC) is associated with the shortest survival duration of any solid cancer. To improve treatment for this disease,…”
Get full text

Clinical, Molecular and Genetic Validation of a Murine Orthotopic Xenograft Model of Pancreatic Adenocarcinoma Using Fresh Human Specimens: e77065 by Walters, Dustin M, Stokes, Jayme B, Adair, Sara J, Stelow, Edward B, Borgman, Cheryl A, Lowrey, Bryce T, Xin, Wenjun, Blais, Edik M, Lee, Jae K, Papin, Jason A

“…Background Relevant preclinical models that recapitulate the key features of human pancreatic ductal adenocarcinoma (PDAC) are needed in order to provide…”
Get full text

A real-time technique for selective molecular imaging and drug delivery in large blood vessels by Patil, Abhay V., Rychak, Joshua J., Taylor, Brooks, Lowrey, Bryce T., Hossack, John A.

“…Current clinical imaging approaches are limited to detecting atherosclerosis when it manifests as an anatomic change. An ultrasound based real-time molecular…”
Get full text